Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases and multi-drug-resistant bacterial infections, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place on May 20, 2024, at NASDAQ World Headquarters in New York, NY. During the conference, Spero's President and CEO, Sath Shukla, will engage in a fireside chat and one-on-one meetings. The session is scheduled from 1:30 - 2:00 PM ET and will be accessible via webcast on Spero's website, with a replay available post-event.
- Spero's participation in a high-profile investor conference enhances visibility and engagement with potential investors and stakeholders.
- CEO Sath Shukla's direct involvement may positively impact investor confidence and highlight leadership's commitment.
- Availability of the webcast and replay increases accessibility and broadens the audience reach.
- Announcement lacks specific details on new developments, financial performance, or clinical trial progress, which may concern some investors.
- No new data or results provided could lead to speculation or uncertainty about the company's current status and future prospects.
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:
| H.C. Wainwright 2ndAnnual BioConnect Investor Conference at NASDAQ | |
| Date: | May 20, 2024 |
| Time: | 1:30 - 2:00 PM ET |
| Webcast Link: | click here |
The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.
- Spero Therapeutics is developing its wholly owned lead product candidate, SPR720 as a novel oral, first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), currently advancing in a Phase 2A proof of concept study. NTM-PD is a rare pulmonary disease caused by non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational oral drug advancing in a Phase 3 registrational trial for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories.
- SPR206 is an innovative, investigational IV-administered direct-acting next generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies. An Investigational New Drug (IND) application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Ashley R. Robinson Managing Director, LifeSci Advisors, LLC
arr@lifesciadvisors.com
(617) 775-5956
Media Inquiries: media@sperotherapeutics.com
FAQ
What is the date and time of Spero Therapeutics' participation in the H.C. Wainwright BioConnect Investor Conference?
Who will represent Spero Therapeutics at the H.C. Wainwright BioConnect Investor Conference?
How can investors access the webcast of Spero Therapeutics' presentation at the H.C. Wainwright BioConnect Investor Conference?
Will there be a replay available for Spero Therapeutics' presentation at the H.C. Wainwright BioConnect Investor Conference?
